Azenta (NASDAQ:AZTA – Get Free Report) and Personalis (NASDAQ:PSNL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Profitability
This table compares Azenta and Personalis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -20.63% | 1.18% | 0.97% |
| Personalis | -147.74% | -49.53% | -37.78% |
Valuation & Earnings
This table compares Azenta and Personalis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.99 | -$55.76 million | ($2.76) | -14.67 |
| Personalis | $80.77 million | 21.31 | -$81.27 million | ($1.17) | -13.57 |
Azenta has higher revenue and earnings than Personalis. Azenta is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Azenta and Personalis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| Personalis | 1 | 7 | 2 | 0 | 2.10 |
Azenta currently has a consensus target price of $41.20, indicating a potential upside of 1.78%. Personalis has a consensus target price of $15.29, indicating a potential downside of 3.70%. Given Azenta’s stronger consensus rating and higher probable upside, analysts plainly believe Azenta is more favorable than Personalis.
Volatility and Risk
Azenta has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Personalis has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.
Institutional and Insider Ownership
99.1% of Azenta shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Azenta beats Personalis on 10 of the 14 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
About Personalis
Personalis is a cancer genomics company that develops sequencing and data-analysis tools for cancer research and personalized cancer care. Its services support pharmaceutical and biotechnology companies, academic researchers, and clinicians studying cancer and evaluating treatments. The company’s offerings include NeXT Personal, a blood-based test designed to detect molecular residual disease and monitor cancer recurrence using circulating tumor DNA. Personalis also provides tumor profiling and immunogenomics services that analyze cancer-related genetic changes and features of the tumor immune environment.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
